Rockville, MD -- (SBWIRE) -- 08/01/2018 -- Nucleic Acid Extraction System Market Prospering as Public and Private Funding Escalates for Clinical Research
A clear understanding of the information stored in cells is essential before therapies and drug formulations can be contemplated. The systems of nucleic acid extraction are at the core of the field of molecular biology, paving way to the discovery of disease-specific DNA sequences. These systems have proven their worth in clinical research of highly prevalent diseases including cancer, microbial infections, and genetic diseases, and their demand is expanding as they can affect virtually all aspects of life sciences. According to the findings of a recent business intelligence study conducted by Fact.MR, the global nucleic acid extraction system market is poised for a fruitful future, with the demand incrementing at an impressive compound annual growth rate during the forecast period of 2018 to 2027.
Request Brochure Copy of the Report @
https://www.factmr.com/connectus/sample?flag=B&rep_id=432
Only A Few Players Holding Major Shares
The report highlights a highly consolidated scenario in terms of global shares in the nucleic acid extraction system market, with QIAGEN, Roche, and Thermo Fisher Scientific as the companies that are considerably ahead of the curve. The analyst of the report attributes the dominance of these companies to their impressive product portfolio and outreach across all important regions and countries. For instance, Thermo Fisher Scientific offers reagent kits for both manual and automated sample processing as well as for automated nucleic acid purification. On the other hand, Roche offers nucleic acid extraction solutions such as MagNA Pure 24 System and MagNA Pure 96 System, both of which are designed to maximize productivity and reducing handling errors.
In the near future too, these companies are expected to retain their prominent positions as there is only a little threat coming from other notable biotechnology companies that may lack financial might or are focused on other market segments. However, innovation is expected to carve niches for some of the other promising players such as Agilent Technologies, Inc., Illumina, Inc., Becton Dickinson and Company, Sigma Aldrich Corp., and Bio-Rad Laboratories Inc.
The focus behind compiling this business publication has been to aid as a reliable tool for a core group of audiences including research associations pertaining to genomics, contract research organizations, and pharmaceutical and biotechnology companies.
Government Support in Emerging Economies Creating New Opportunities
Some of the key factors primed to reflect positively over the nucleic acid extraction system market are: increasing public and private funding on life science research, technological advancements and increasing focus on automation in order to achieve greater efficiencies and reduce duration of clinical trials, and widespread opportunities in the emerging economies. A number of companies have now started offering their in-house products that are capable in generating high quality extractions with shortened turnaround phases. A number of governments have made a point to make agreements with top research organizations and institutes in order to augment the research activities pertaining to molecular biology.
On the other hand, high cost of automated instruments is causing significant hurdle for the market to flourishing. In addition to that, owing to the uncertainties of the results as the experiments can be vastly complex, products turn more expensive than expected. Those research groups with limited budgets then refrain from further progress and that hinders the demand potential. Nevertheless, the increasing inclination towards molecular diagnostics and personalized medicine is expected to create new opportunities in the near future.
Request TOC of this Report@ Request TOC of this Report@ https://www.factmr.com/connectus/sample?flag=B&rep_id=432
Based on type, the market for nucleic acid extraction systems can be segmented into mRNA, micro RNA, total RNA, blood DNA, PCR clean up, genomic DNA, and plasmid DNA. Geographically, the report has evaluated the demand potential of all important and investable regions and countries.